期刊文献+

Mutation analysis of the checkpoint kinase 2 gene in colorectal cancer cell lines 被引量:1

Mutation analysis of the checkpoint kinase 2 gene in colorectal cancer cell lines
原文传递
导出
摘要 Background Checkpoint kinase 2 (CHK2) is a DNA damage-activated protein kinase which is involved in cell cycle checkpoint control, CHK2 gene could be a candidate gene for colorectal cancer susceptibility, But there are few systematic reports on mutation of CHK2 in colorectal cancer. Methods The mutations of all 14 exons of CHK2 in 56 colorectal cancer cell lines were screened systematically, using denaturing high-performance liquid chromatography (DHPLC) to screen the mismatches of the CHK2 exons amplified products, and then the suspected mutant cell lines were scanned by nucleotide sequence analysis. Results VACO400 in CHK2 exon la was suspected to have mutation by DHPLC and confirmed by sequence, but this was nonsense mutation. C106, CX-1, HT-29, SK01, SW480, SW620 and VACO400 in CHK2 exon lb were confirmed to have the same nonsense mutation in 11609 A〉G. DLD-1 and HCT-15 in CHK2 exon 2 were confirmed to have missense mutation R145W, which was heterozygous C〉T missense mutation at nucleotide 433, leading to an Arg〉Trp substitution within the FHA domain. Conclusions The CHK2 mutation in colorectal cancer is a low frequency event, There are just 10 cell lines to have sequence variations in all the 14 exons in 56 colorectal cancer cell lines and only DLD-1/HCT-15 had heterozygous missense mutation. These findings may give useful information of susceptibility of colorectal cancer as single nucleotide polvmorphvsim. Background Checkpoint kinase 2 (CHK2) is a DNA damage-activated protein kinase which is involved in cell cycle checkpoint control, CHK2 gene could be a candidate gene for colorectal cancer susceptibility, But there are few systematic reports on mutation of CHK2 in colorectal cancer. Methods The mutations of all 14 exons of CHK2 in 56 colorectal cancer cell lines were screened systematically, using denaturing high-performance liquid chromatography (DHPLC) to screen the mismatches of the CHK2 exons amplified products, and then the suspected mutant cell lines were scanned by nucleotide sequence analysis. Results VACO400 in CHK2 exon la was suspected to have mutation by DHPLC and confirmed by sequence, but this was nonsense mutation. C106, CX-1, HT-29, SK01, SW480, SW620 and VACO400 in CHK2 exon lb were confirmed to have the same nonsense mutation in 11609 A〉G. DLD-1 and HCT-15 in CHK2 exon 2 were confirmed to have missense mutation R145W, which was heterozygous C〉T missense mutation at nucleotide 433, leading to an Arg〉Trp substitution within the FHA domain. Conclusions The CHK2 mutation in colorectal cancer is a low frequency event, There are just 10 cell lines to have sequence variations in all the 14 exons in 56 colorectal cancer cell lines and only DLD-1/HCT-15 had heterozygous missense mutation. These findings may give useful information of susceptibility of colorectal cancer as single nucleotide polvmorphvsim.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2007年第23期2119-2123,共5页 中华医学杂志(英文版)
基金 China-Korea Young Scientist Exchange Program(2004), Biomedical Research Institute of Kyungpook National University Hospital.
关键词 checkpoint kinase 2 colorectal cancer denaturing high-performance liquid chromatography cell line colorectal cancer checkpoint kinase 2 colorectal cancer denaturing high-performance liquid chromatography cell line, colorectal cancer
  • 相关文献

参考文献12

  • 1Ana Sánchez de Abajo,Miguel de la Hoya,Javier Godino,Vicente Furió,Alicia Tosar,Pedro Pérez-Segura,Eduardo Díaz-Rubio,Trinidad Caldés.The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families[J].Familial Cancer.2005(2)
  • 2Pietro Taverna,Lili Liu,Amy J. Hanson,Anne Monks,Stanton L. Gerson.Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen[J].Cancer Chemotherapy and Pharmacology.2000(6)
  • 3van Puijenbroek M,van Asperen CJ,van Mil A,Devilee P,van Wezel T,Morreau H.Homozygosity for a CHEK2~*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype[].Journal of Paleopathology.2005
  • 4Williams LH,Choong D,Johnson SA,Campbell IG.Genetic and epigenetic analysis of CHEK2 in sporadic breast,colon,and ovarian cancers[].Clinical Cancer Research.2006
  • 5Lipton L,Fleischmann C,Sieber OM,Thomas HJ,Hodgson SV,Tomlinson IP,et al.Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma[].Cancer Letters.2003
  • 6de,Jong,MM,Nolte,IM,Te Meerman,GJ.Colorectal cancer and the CHEK2 1100delC mutation[].Genes Chromosomes and Cancer.2005
  • 7Vahteristo,P,Bartkova,J,Eerola,H,Syrjakoski,K,Ojala,S,Kilpivaara,O,Tamminen,A,Kononen,J,Aittomaki,K,Heikkila,P,Holli,K,Blomqvist,C,Bartek,J,Kallioniemi,OP,Nevanlinna,H.A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer[].The American Journal of Human Genetics.2002
  • 8Meijers-Heijboer,H,van den,Ouweland,A,Klijn,J,Wasielewski,M,de,Snoo,A,Oldenburg,R.Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations[].Nature Genetics.2002
  • 9.CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies[].The American Journal of Human Genetics.2004
  • 10Blasina A,de Weyer IV,Laus MC,Luyten WH,Parker AE,McGowan CH.A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase[].Current Biology.1999

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部